Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Dr Tony Rush, Director of Neuroscience, and Dr Eddy Stevens, CSO, speak with Dr Chris Mathes, CCO, about ion channel screening at Metrion. Dr Katie Puddefoot, Senior Scientist and Dr Nicola Secomandi, Senior Scientist give deeper insight into manual patch, and recording from primary neurons to provide in-depth understanding of drug mechanism of action.
Aligos Therapeutics and Metrion explore key approaches to cardiovascular safety screening in drug discovery.
Academic case study on Nav1.9 as a drug target by Associate Professor David Bulmer (University of Cambridge). Overview of Metrion’s newly developed Nav1.9 screening assays by Metrion CSO, Dr. Eddy Stevens.